Abstract
Alzheimer’s Disease: New Beginnings focuses on the future promise for therapeutic breakthroughs in light of notable clinical trial failures. We used a combination of scientometric evaluations to determine the most promising new approaches as well as soliciting insights from leaders in each of the major areas of Alzheimer’s disease research. By combining these two approaches, we recruited authors from the entire outlook spectrum of those who feel an elusive breakthrough might still be a few, well-placed tweaks away to those who feel that they are launching entirely new investigative paradigms. These scholars present an open-eyed path forward. Now is the most exciting period of a generation in our field as old dogma makes way for new insight, whether it be new approaches to clinical trials, improved biomarker-based diagnostics, population-based studies, prevention, metabolism, or further refinement of the role of inflammation, genetics, tau, and amyloid-β.